SCHEMBL9894630

SCHEMBL9894630

CO/C=C(\C(=O)OC)c1ccccc1COc1cc(F)cc(OCCOc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 7/20 0.47
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CAPN1 P07384 1/20 0.40
KAT6A Q92794 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894631 1.00 HIF1A (0.47) HIF1AKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL9894634 1.00 HIF1A (0.47) HIF1AKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL9894190 0.93 HIF1A (0.49) HIF1AKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL9894187 0.93 HIF1A (0.49) HIF1AKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL9894188 0.93 HIF1A (0.49) HIF1AKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL9894632 0.91 HIF1A (0.48) HIF1AKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL9894317 0.90 HIF1A (0.55) HIF1AL3MBTL1CAPN1MAPT
SCHEMBL9894312 0.90 HIF1A (0.55) HIF1AL3MBTL1CAPN1MAPT
SCHEMBL9894313 0.90 HIF1A (0.55) HIF1AL3MBTL1CAPN1MAPT
SCHEMBL7172810 0.89 HIF1A (0.50) HIF1AKDM4ESMN1; SMN2TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US claimed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP claimed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US claimed
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US disclosed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 HIF1A 1/4885KDM4E 533/4885SMN1; SMN2 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.